Indirect Costs Associated with Diabetic Macular Edema (DME) in Colombia
Author(s)
Claudia A. López-Cabra, MSc, Médica epidemióloga1, Ángela Daniela Rodríguez, MSc, Economist2, Diana Smith Lopez, MSc, Economist2, Oscar A. Peñuela, MSc, Médico1, Juliana Nuñoz, Esp., Médica oftalmóloga1, Shirley Monsalve, Market Access1, wilson Mayorga Mogollon, MSc, Economist2;
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
Presentation Documents
OBJECTIVES: To calculate the indirect costs associated with DME over a period of 2 years (2022 to 2023), based on data from the survey 'Market Research Survey focusing on the management and treatment of diabetic retinopathy (DR) - with and without diabetic macular edema (DME)' conducted globally, in which Colombia was a participating country
METHODS: The surveyed patients in Colombia were 325. The estimation was made in terms of productivity loss calculated from the time spent on transportation and healthcare attention, including medical appointments, administration of Anti-VEGF therapies, laser treatments, and corticosteroids with/without caregiver, adjusted for the patient's age. The average transportation cost from the cities where the surveyed clinics were located was obtained, and the average monthly salary of a worker/caregiver for 2022 from the national survey “Gran Encuesta Integrada de Hogares (GEIH)” was calculated to estimate the foregone income of the caregiver and patient, the latter weighted by age and severe vision loss reported by the Global Burden of Disease (GBD) at 0.314. The results are reported for 2024, updated based on the Consumer Price Index (CPI)
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), total indirect costs for all surveyed patients and caregivers were USD$592.034 for analyzed years (USD$911 per patient/year). Transportation costs (including patients and caregivers) were estimated at USD$225.490 (USD$347 per patient/year), the foregone income for caregivers' time spent attending medical appointments at USD$41,415 (USD$142 per patient/year) and the productivity losses for patients under 60 years old (33,5%) was USD$325.130 (USD$2.986 per patient/year)
CONCLUSIONS: Indirect cost of DME for the patient/caregiver in a two-year period was USD$1,822. The increase in these indirect costs is related to the frequency of the treatment, highlighting the benefit that a treatment scheme such as the treat and extent could provide in terms of reduction of these costs
METHODS: The surveyed patients in Colombia were 325. The estimation was made in terms of productivity loss calculated from the time spent on transportation and healthcare attention, including medical appointments, administration of Anti-VEGF therapies, laser treatments, and corticosteroids with/without caregiver, adjusted for the patient's age. The average transportation cost from the cities where the surveyed clinics were located was obtained, and the average monthly salary of a worker/caregiver for 2022 from the national survey “Gran Encuesta Integrada de Hogares (GEIH)” was calculated to estimate the foregone income of the caregiver and patient, the latter weighted by age and severe vision loss reported by the Global Burden of Disease (GBD) at 0.314. The results are reported for 2024, updated based on the Consumer Price Index (CPI)
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), total indirect costs for all surveyed patients and caregivers were USD$592.034 for analyzed years (USD$911 per patient/year). Transportation costs (including patients and caregivers) were estimated at USD$225.490 (USD$347 per patient/year), the foregone income for caregivers' time spent attending medical appointments at USD$41,415 (USD$142 per patient/year) and the productivity losses for patients under 60 years old (33,5%) was USD$325.130 (USD$2.986 per patient/year)
CONCLUSIONS: Indirect cost of DME for the patient/caregiver in a two-year period was USD$1,822. The increase in these indirect costs is related to the frequency of the treatment, highlighting the benefit that a treatment scheme such as the treat and extent could provide in terms of reduction of these costs
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE19
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)